SG11201909104PA - Therapeutic or prophylactic agent for peripheral neuropathies - Google Patents

Therapeutic or prophylactic agent for peripheral neuropathies

Info

Publication number
SG11201909104PA
SG11201909104PA SG11201909104PA SG11201909104PA SG 11201909104P A SG11201909104P A SG 11201909104PA SG 11201909104P A SG11201909104P A SG 11201909104PA SG 11201909104P A SG11201909104P A SG 11201909104PA
Authority
SG
Singapore
Prior art keywords
therapeutic
prophylactic agent
peripheral neuropathies
neuropathies
peripheral
Prior art date
Application number
Inventor
Kojiro Hara
Tomohiko Suzuki
Chihiro Yoshida
Koji Takeo
Koji Shimoda
Naoki Izumimoto
Kazumi Nishimura
Rieko Naguro
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of SG11201909104PA publication Critical patent/SG11201909104PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
SG11201909104P 2017-03-31 2018-03-30 Therapeutic or prophylactic agent for peripheral neuropathies SG11201909104PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017071339 2017-03-31
JP2017071329 2017-03-31
PCT/JP2018/013536 WO2018181860A1 (en) 2017-03-31 2018-03-30 Therapeutic or prophylactic agent for peripheral neuropathies

Publications (1)

Publication Number Publication Date
SG11201909104PA true SG11201909104PA (en) 2019-11-28

Family

ID=63678147

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909104P SG11201909104PA (en) 2017-03-31 2018-03-30 Therapeutic or prophylactic agent for peripheral neuropathies

Country Status (17)

Country Link
US (1) US20200030293A1 (en)
EP (1) EP3603639A4 (en)
JP (1) JP7163906B2 (en)
KR (1) KR102633957B1 (en)
CN (1) CN110446494A (en)
AU (1) AU2018245892B2 (en)
BR (1) BR112019019614A2 (en)
CA (1) CA3057818A1 (en)
IL (1) IL269502B (en)
MX (1) MX2019010967A (en)
MY (1) MY201356A (en)
PH (1) PH12019502261A1 (en)
RU (1) RU2770307C2 (en)
SG (1) SG11201909104PA (en)
TW (1) TWI774746B (en)
WO (1) WO2018181860A1 (en)
ZA (1) ZA201906762B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3123833A1 (en) 2018-12-26 2020-07-02 Toray Industries, Inc. Cyclic amine derivative as agent for promoting advillin function, and novel cyclic amine derivative and pharmaceutical use thereof
WO2021172488A1 (en) * 2020-02-28 2021-09-02 東レ株式会社 Cyclic amine derivative and pharmaceutical use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101341692B1 (en) * 2011-03-16 2013-12-20 동아에스티 주식회사 Composition comprising the extract of herbal combination for preventing or treating diabetic peripheral neuropathy
SG194138A1 (en) * 2011-04-11 2013-11-29 Abbvie Inc Parp inhibitors for the treatment of cipn
WO2013147160A1 (en) * 2012-03-29 2013-10-03 東レ株式会社 Cyclic amine derivative and use thereof for medical purposes
AU2013268725B2 (en) * 2012-05-31 2017-02-16 Asahi Kasei Pharma Corporation Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent
TWI652264B (en) * 2013-09-26 2019-03-01 東麗股份有限公司 Cyclic amine derivatives and their medical uses
US10173999B2 (en) * 2015-02-27 2019-01-08 Toray Industries, Inc. Cyclic amine derivative and pharmaceutical use thereof
JP2017071329A (en) 2015-10-08 2017-04-13 三菱自動車工業株式会社 Vehicle heating system
JP6565574B2 (en) 2015-10-08 2019-08-28 住友ゴム工業株式会社 Winter tires

Also Published As

Publication number Publication date
US20200030293A1 (en) 2020-01-30
JP7163906B2 (en) 2022-11-01
AU2018245892B2 (en) 2022-02-24
AU2018245892A1 (en) 2019-10-31
IL269502A (en) 2019-11-28
ZA201906762B (en) 2023-04-26
RU2770307C2 (en) 2022-04-15
CN110446494A (en) 2019-11-12
KR20190129036A (en) 2019-11-19
MX2019010967A (en) 2020-01-15
KR102633957B1 (en) 2024-02-06
PH12019502261A1 (en) 2020-07-06
RU2019134050A (en) 2021-04-30
CA3057818A1 (en) 2018-10-04
TW201841903A (en) 2018-12-01
BR112019019614A2 (en) 2020-04-14
MY201356A (en) 2024-02-20
RU2019134050A3 (en) 2021-05-24
WO2018181860A1 (en) 2018-10-04
JPWO2018181860A1 (en) 2020-02-13
IL269502B (en) 2022-09-01
TWI774746B (en) 2022-08-21
EP3603639A4 (en) 2021-01-27
EP3603639A1 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
EP3732195A4 (en) Cytotoxicity-inducing therapeutic agent
GB201709456D0 (en) Therapeutic agents
IL275482A (en) Esketamine for the treatment of depression
EP3619238A4 (en) Cytotoxicity-inducing therapeutic agent
EP3400940A4 (en) Prophylactic or therapeutic agent for delirium
ZA201906762B (en) Therapeutic or prophylactic agent for peripheral neuropathies
EP3492091A4 (en) Prophylactic or therapeutic agent for vascular disorder
GB201700553D0 (en) Therapeutic agents
EP3120852A4 (en) Prophylactic and/or therapeutic agent for immune diseases
SG11202001484QA (en) Cytocidal agent
GB201700526D0 (en) Therapeutic use
EP3636256A4 (en) Prophylactic or therapeutic agent for hyperactive bladder
EP3560527A4 (en) Tissue healing agent
EP3272349A4 (en) Therapeutic and/or prophylactic agent for lewy body diseases
GB2569225B (en) Prophylactic treatment
GB201702921D0 (en) Therapeutic agent
GB201718985D0 (en) Treatment
GB201711677D0 (en) Combination treatment
GB201702052D0 (en) Therapeutic agents
GB201702047D0 (en) Therapeutic agents
GB201701631D0 (en) Therapeutic agents
GB201701570D0 (en) Therapeutic agents
GB201700567D0 (en) Therapeutic agents
GB201713650D0 (en) Treatment
GB201713113D0 (en) Combination therapy